Goldman Sachs Upgrades Arcus Biosciences to Buy, Raises Price Target to $28
Benzinga Newsdesk 10 months ago
NewsUpgradesPrice TargetAnalyst Ratings
Goldman Sachs analyst Richard Law upgrades Arcus Biosciences (NYSE:RCUS) from Neutral to Buy and raises the price target from $16 to $28.
Goldman Sachs analyst Richard Law upgrades Arcus Biosciences (NYSE:RCUS) from Neutral to Buy and raises the price target from $16 to $28.